HEFT Repository

Screening for Hypogonadism in Primary Healthcare: How to do this Effectively.

Livingston, Mark and Jones, Richard and Hackett, Geoff and Donnahey, Gemma and Moreno, Gabriela Yc and Duff, Christopher J and Heald, Adrian H (2018) Screening for Hypogonadism in Primary Healthcare: How to do this Effectively. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. ISSN 1439-3646.

Full text not available from this repository.
Official URL: https://www.thieme-connect.com/DOI/DOI?10.1055/s-0...

Abstract

BACKGROUND

Testosterone, the most important androgen produced by the testes, plays an integral role in male health. Testosterone levels are increasingly being checked in primary healthcare as awareness of the risks of male hypogonadism grows.

AIM

To investigate what tests are performed to screen for hypogonadism and to exclude secondary hypogonadism.

DESIGN AND SETTING

All participants attended general practices in the UK.

METHODS

Data search was performed using the EMIS®: clinical database (provider of the majority of GP operating systems in Cheshire). The anonymised records of male patients aged 18-98 years who had undergone a check of serum testosterone during a 10-year period were analysed.

RESULTS

Overall screening rate was 4.3%. Of 8 788 men with a testosterone result, 1 924 men (21.9%) had a total testosterone level <10 nmol/L. Just 689 of 8 788 men (7.8%) had a sex hormone-binding globulin (SHBG) result, corresponding to 30.5% of those potentially hypogonadal. Estimated free testosterone was negatively associated with BMI (Spearman's rho -0.2, p<0.001) as was total testosterone in the over 50 s. Of 1 924 potentially hypogonadal men with a serum testosterone <10 nmol/L, 588 of 1 924 (30.6%) had a check of serum prolactin. 46.3% and 41.7% had LH and FSH measured, respectively. Only 19.1% of 1 924 men with a hypogonadal total testosterone level were subsequently put on testosterone replacement. The percentage of men in the relatively socially disadvantaged category was similar for both eugonadal and hypogonadal men with a much higher rate of screening for hypogonadism in more socially advantaged men.

CONCLUSIONS

Screening in primary healthcare identified a significant minority of men who had potential hypogonadism. Interpretation of a low serum testosterone requires measurement of serum prolactin, LH and FSH in order to rule out secondary hypogonadism. We suggest that this becomes part of routine screening with a balanced screening approach across the socioeconomic spectrum.

Item Type: Article
Subjects: WJ Urogenital system. Urology
Divisions: Planned IP Care > Urology
Related URLs:
Depositing User: Miss Emily Johnson
Date Deposited: 26 Jan 2018 14:31
Last Modified: 26 Jan 2018 14:31
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1577

Actions (login required)

View Item View Item